FundedIQ
Health Care

Encare

Encare was established in 2009 to implement the ERAS Protocols on a global basis by - providing training to health care professionals on the ERAS Protocols - providing an interactive and web-based information system for evidence based - best practice management (EBM) The company has developed an interactive, user-friendly interface for the collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence. The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings. Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States. The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery.

encare.net Stockholm, Sweden 11-50 employees
Total raised
$0k
Rounds
1
Latest
Series A
May 2023

Encare was established in 2009 to implement the ERAS Protocols on a global basis by - providing training to health care professionals on the ERAS Protocols - providing an interactive and web-based information system for evidence based - best practice management (EBM) The company has developed an interactive, user-friendly interface for the collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence. The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings. Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States. The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery.

Encare has raised $0k across 1 round. Its most recent round was a Series A of $0k in May 2023. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
May 8, 2023
Series A
$0k

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Encare is featured in

Similar companies

Celluminova

Celluminova specializes in the development of new tools for stem cell research, including cancer stem cells.

Series Unknown $2.1M
Klaria Pharma Holding

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses.

Series Unknown $2.6M
ChemoTech

ChemoTech is a Scandinavian company based at Medicon Village in Lund, Sweden. The company’s founders have extensive experience of cancer treatment through surgical oncology and clinical development. The company is dedicated to using its unique patented know-how to develop innovation in cancer care through genuine research and clinical trials.

Series Unknown $640k
Spermosens

Spermosens is a medical equipment manufacturer that produces technologies for diagnosing male-factor infertility.

Series Unknown $520k
IRLAB Therapeutics

IRLAB is a Swedish drug discovery and development company providing novel treatments for disorders of the brain. IRLAB is engaged in programmes targeting core dysfunctions in Parkinson’s disease and dementias. IRLAB has identified, and is currently engaged in clinical development of, two novel compounds aimed at offering improved clinical benefit for patients with Parkinson’s disease.

Series Unknown $11.0M
AlzeCure Pharma

The AlzeCure Foundation is focused on the development of novel diagnostics and therapeutics for PD, AD and related neurodegenerative disorders. Conceptually, AlzeCure is an industry-standard incubator for novel projects. It comprises key professionals exhibiting complementary expertise from molecule to man.

Series Unknown $3.3M
Blodtrycksdoktorn

Blodtrycksdoktorn is an evidence-based digital innovation that uses telemedicine, mobile health technology, and home blood pressure monitoring (HBPM) to provide a novel approach to managing hypertension.

Series Unknown $760k
BiBBInstruments

B! BB Instruments develops an instrument that allows quick and easy sampling of suspected cancer tumors by drilling into the tissue. This makes it possible to reach deep-lying tumors. This differs from today's methods that are difficult to capture deeply lying tissue.

Series Unknown $4.5M
Observe Medical

Observe Medical has developed a revolutionary digital urine meter - Sippi. Sippi is an easy-to-use application that monitors urine production via a bag application connected to a piece of software. Sippi is fully automatic during the length of the treatment.

Series Unknown $1.5M
Beactica Therapeutics AB

Beactica Therapeutics AB is a precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics to treat genetically defined cancers with significant unmet clinical need. Beactica’s approach is centered around targeting disease proteins with synthetic lethality vulnerabilities by applying its molecular interaction-based drug discovery engine to generate novel small molecule across synergistic modalities, including allosteric modulators and targeted protein degraders (PROTACs). Beactica deliver value to patients and shareholders by advancing its programmes into early clinical trials.

Series Unknown $3.0M
Loovi

Loovi is a health technology firm that provides a doctor-led, data-driven longevity solution. It focuses on preventive health by using biomarker testing and tailored coaching.

Angel $1.2M
Yazen

Yazen is a digital healthcare provider that offers tailored weight loss programs, combining medical treatments with lifestyle coaching. The platform connects users with a team of experts, including doctors, dietitians, and personal trainers, to create individualized weight management plans.

Series Unknown $7.7M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.